Literature DB >> 16844727

Incidence and mortality of idiopathic pulmonary fibrosis and sarcoidosis in the UK.

J Gribbin1, R B Hubbard, I Le Jeune, C J P Smith, J West, L J Tata.   

Abstract

BACKGROUND: Idiopathic pulmonary fibrosis (IPF) and sarcoidosis are common diagnoses in patients attending chest clinics, but little is known about the epidemiology of these diseases. We used data from a general practice database to provide information on the current incidence of IPF and sarcoidosis in the UK.
METHODS: Data were extracted for all patients with a diagnosis of IPF or sarcoidosis between 1991 and 2003. The whole population of the database was used to calculate disease incidence stratified by age, sex, region, and time period. Poisson regression was used to compare the incidence between populations and Cox regression was used to compare survival between populations.
RESULTS: 920 cases of IPF (mean age 71 years, 62% male) and 1019 cases of sarcoidosis (mean age 47 years, 47% male) were identified. The overall incidence rate per 100 000 person-years was 4.6 for IPF and 5.0 for sarcoidosis. The incidence of IPF increased progressively between 1991 and 2003 (p<0.00001), and was highest in Northern England and Scotland (p<0.0001). The survival of patients with IPF was stable over time. In contrast, the incidence of sarcoidosis was highest in London, West Midlands and Northern Ireland and remained stable over time.
CONCLUSIONS: The incidence of IPF has more than doubled between 1990 and 2003; this is not due to the ageing of the UK population or an increased ascertainment of milder cases. The incidence of sarcoidosis has not changed during this time period. Our findings suggest that more than 4000 new cases of IPF and 3000 new cases of sarcoidosis are currently diagnosed each year in the UK.

Entities:  

Mesh:

Year:  2006        PMID: 16844727      PMCID: PMC2121155          DOI: 10.1136/thx.2006.062836

Source DB:  PubMed          Journal:  Thorax        ISSN: 0040-6376            Impact factor:   9.139


  14 in total

1.  Lung cancer and cryptogenic fibrosing alveolitis. A population-based cohort study.

Authors:  R Hubbard; A Venn; S Lewis; J Britton
Journal:  Am J Respir Crit Care Med       Date:  2000-01       Impact factor: 21.405

2.  Occupational and environmental risk factors for idiopathic pulmonary fibrosis: a multicenter case-control study. Collaborating Centers.

Authors:  K B Baumgartner; J M Samet; D B Coultas; C A Stidley; W C Hunt; T V Colby; J A Waldron
Journal:  Am J Epidemiol       Date:  2000-08-15       Impact factor: 4.897

3.  Feasibility study and methodology to create a quality-evaluated database of primary care data.

Authors:  Alison Bourke; Hassy Dattani; Michael Robinson
Journal:  Inform Prim Care       Date:  2004

4.  Mortality rates from cryptogenic fibrosing alveolitis in seven countries.

Authors:  R Hubbard; I Johnston; D B Coultas; J Britton
Journal:  Thorax       Date:  1996-07       Impact factor: 9.139

5.  Occupational exposure to metal or wood dust and aetiology of cryptogenic fibrosing alveolitis.

Authors:  R Hubbard; S Lewis; K Richards; I Johnston; J Britton
Journal:  Lancet       Date:  1996-02-03       Impact factor: 79.321

6.  Determinants of survival in idiopathic pulmonary fibrosis.

Authors:  D A Schwartz; R A Helmers; J R Galvin; D S Van Fossen; K L Frees; C S Dayton; L F Burmeister; G W Hunninghake
Journal:  Am J Respir Crit Care Med       Date:  1994-02       Impact factor: 21.405

7.  The epidemiology of interstitial lung diseases.

Authors:  D B Coultas; R E Zumwalt; W C Black; R E Sobonya
Journal:  Am J Respir Crit Care Med       Date:  1994-10       Impact factor: 21.405

8.  Rising mortality from cryptogenic fibrosing alveolitis.

Authors:  I Johnston; J Britton; W Kinnear; R Logan
Journal:  BMJ       Date:  1990-11-03

9.  Clinical characteristics of patients in a case control study of sarcoidosis.

Authors:  R P Baughman; A S Teirstein; M A Judson; M D Rossman; H Yeager; E A Bresnitz; L DePalo; G Hunninghake; M C Iannuzzi; C J Johns; G McLennan; D R Moller; L S Newman; D L Rabin; C Rose; B Rybicki; S E Weinberger; M L Terrin; G L Knatterud; R Cherniak
Journal:  Am J Respir Crit Care Med       Date:  2001-11-15       Impact factor: 21.405

10.  High prevalence of familial sarcoidosis in an Irish population.

Authors:  N J Brennan; P Crean; J P Long; M X Fitzgerald
Journal:  Thorax       Date:  1984-01       Impact factor: 9.139

View more
  163 in total

1.  Prevalence and incidence of interstitial lung diseases in a multi-ethnic county of Greater Paris.

Authors:  Boris Duchemann; Isabella Annesi-Maesano; Camille Jacobe de Naurois; Shreosi Sanyal; Pierre-Yves Brillet; Michel Brauner; Marianne Kambouchner; Sophie Huynh; Jean Marc Naccache; Raphael Borie; Jacques Piquet; Arsène Mekinian; Jerôme Virally; Yurdagul Uzunhan; Jacques Cadranel; Bruno Crestani; Olivier Fain; Francois Lhote; Robin Dhote; Nathalie Saidenberg-Kermanac'h; Paul-André Rosental; Dominique Valeyre; Hilario Nunes
Journal:  Eur Respir J       Date:  2017-08-03       Impact factor: 16.671

Review 2.  Idiopathic pulmonary fibrosis-an epidemiological and pathological review.

Authors:  Andrea T Borchers; Christopher Chang; Carl L Keen; M Eric Gershwin
Journal:  Clin Rev Allergy Immunol       Date:  2011-04       Impact factor: 8.667

3.  Gender influences the response to experimental silica-induced lung fibrosis in mice.

Authors:  David M Brass; Sean P McGee; Mary K Dunkel; Sarah M Reilly; Jacob M Tobolewski; Tara Sabo-Attwood; Cheryl L Fattman
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2010-08-20       Impact factor: 5.464

4.  Effect of treatment guidelines on the initial management of idiopathic pulmonary fibrosis.

Authors:  Jeffrey C Munson; Maryl Kreider; Zhen Chen; Jason D Christie; Stephen E Kimmel
Journal:  Br J Clin Pharmacol       Date:  2010-07       Impact factor: 4.335

5.  Fibrocytes Regulate Wilms Tumor 1-Positive Cell Accumulation in Severe Fibrotic Lung Disease.

Authors:  Vishwaraj Sontake; Shiva K Shanmukhappa; Betsy A DiPasquale; Geereddy B Reddy; Mario Medvedovic; William D Hardie; Eric S White; Satish K Madala
Journal:  J Immunol       Date:  2015-09-14       Impact factor: 5.422

6.  Regulation of Collagen V Expression and Epithelial-Mesenchymal Transition by miR-185 and miR-186 during Idiopathic Pulmonary Fibrosis.

Authors:  Guang-Sheng Lei; Hannah L Kline; Chao-Hung Lee; David S Wilkes; Chen Zhang
Journal:  Am J Pathol       Date:  2016-07-05       Impact factor: 4.307

Review 7.  Sex-specific lung diseases: effect of oestrogen on cultured cells and in animal models.

Authors:  Bosung Shim; Gustavo Pacheco-Rodriguez; Jiro Kato; Thomas N Darling; Martha Vaughan; Joel Moss
Journal:  Eur Respir Rev       Date:  2013-09-01

Review 8.  It's all about sex: gender, lung development and lung disease.

Authors:  Michelle A Carey; Jeffrey W Card; James W Voltz; Samuel J Arbes; Dori R Germolec; Kenneth S Korach; Darryl C Zeldin
Journal:  Trends Endocrinol Metab       Date:  2007-08-30       Impact factor: 12.015

9.  Alveolar epithelial cells in idiopathic pulmonary fibrosis display upregulation of TRAIL, DR4 and DR5 expression with simultaneous preferential over-expression of pro-apoptotic marker p53.

Authors:  Khondoker M Akram; Nicola J Lomas; Nicholas R Forsyth; Monica A Spiteri
Journal:  Int J Clin Exp Pathol       Date:  2014-01-15

10.  The Shh/Gli signaling cascade regulates myofibroblastic activation of lung-resident mesenchymal stem cells via the modulation of Wnt10a expression during pulmonary fibrogenesis.

Authors:  Honghui Cao; Xiang Chen; Jiwei Hou; Cong Wang; Zou Xiang; Yi Shen; Xiaodong Han
Journal:  Lab Invest       Date:  2019-09-20       Impact factor: 5.662

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.